Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Oxurion

DB:TG4
Snowflake Description

Excellent balance sheet with limited growth.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
TG4
DB
€98M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Oxurion NV, an integrated biopharmaceutical company, develops and commercializes medicines that address unmet clinical needs in ophthalmology in Belgium and internationally. The last earnings update was 5 days ago. More info.


Add to Portfolio Compare Print
  • Oxurion has significant price volatility in the past 3 months.
TG4 Share Price and Events
7 Day Returns
2%
DB:TG4
5.2%
DE Biotechs
4.3%
DE Market
1 Year Returns
-35.5%
DB:TG4
-7.4%
DE Biotechs
-14.2%
DE Market
TG4 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Oxurion (TG4) 2% -6% -19.5% -35.5% -22.7% -55.8%
DE Biotechs 5.2% -3.3% -20.3% -7.4% 19.5% -9.4%
DE Market 4.3% -9% -21.6% -14.2% -19.6% -25.6%
1 Year Return vs Industry and Market
  • TG4 underperformed the Biotechs industry which returned -7.4% over the past year.
  • TG4 underperformed the Market in Germany which returned -14.2% over the past year.
Price Volatility
TG4
Industry
5yr Volatility vs Market
Related Companies

Value

 Is Oxurion undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Oxurion. This is due to cash flow or dividend data being unavailable. The share price is €2.515.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Oxurion's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Oxurion's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:TG4 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in EUR €-1.35
ENXTBR:OXUR Share Price ** ENXTBR (2020-04-08) in EUR €2.57
Europe Biotechs Industry PE Ratio Median Figure of 24 Publicly-Listed Biotechs Companies 43.07x
Germany Market PE Ratio Median Figure of 402 Publicly-Listed Companies 17.07x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Oxurion.

DB:TG4 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= ENXTBR:OXUR Share Price ÷ EPS (both in EUR)

= 2.57 ÷ -1.35

-1.9x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Oxurion is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Oxurion is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Oxurion's expected growth come at a high price?
Raw Data
DB:TG4 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -1.9x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts
-20.2%per year
Europe Biotechs Industry PEG Ratio Median Figure of 19 Publicly-Listed Biotechs Companies 1.71x
Germany Market PEG Ratio Median Figure of 256 Publicly-Listed Companies 1.24x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Oxurion, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Oxurion's assets?
Raw Data
DB:TG4 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in EUR €1.39
ENXTBR:OXUR Share Price * ENXTBR (2020-04-08) in EUR €2.57
Germany Biotechs Industry PB Ratio Median Figure of 14 Publicly-Listed Biotechs Companies 3.37x
Germany Market PB Ratio Median Figure of 573 Publicly-Listed Companies 1.47x
DB:TG4 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= ENXTBR:OXUR Share Price ÷ Book Value per Share (both in EUR)

= 2.57 ÷ 1.39

1.85x

* Primary Listing of Oxurion.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Oxurion is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Oxurion's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Oxurion has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Oxurion expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-20.2%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Oxurion expected to grow at an attractive rate?
  • Unable to compare Oxurion's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Oxurion's earnings growth to the Germany market average as it is expected to be loss making during the next 1-3 years.
  • Oxurion's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:TG4 Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:TG4 Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts -20.2%
DB:TG4 Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 1 Analysts 75.6%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 38.2%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.2%
Germany Market Earnings Growth Rate Market Cap Weighted Average 14.1%
Germany Market Revenue Growth Rate Market Cap Weighted Average 3.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:TG4 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
All numbers in EUR Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:TG4 Future Estimates Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-12-31 263 -97 1
2023-12-31 83 -165 1
2022-12-31 0 -159 1
2021-12-31 0 -67 1
2020-12-31 0 -42 1
2020-04-08
DB:TG4 Past Financials Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income *
2019-12-31 4 -31 -52
2019-09-30 4 -27 -54
2019-06-30 3 -24 -57
2019-03-31 4 -27 -48
2018-12-31 5 -31 -38
2018-09-30 6 -7 -8
2018-06-30 7 16 23
2018-03-31 6 21 23
2017-12-31 6 26 23
2017-09-30 6 0 -19
2017-06-30 6 -27 -61
2017-03-31 6 -23 -60

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Oxurion is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Oxurion's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:TG4 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below

All data from Oxurion Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:TG4 Future Estimates Data
Date (Data in EUR Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-12-31 -1.25 -1.25 -1.25 1.00
2023-12-31 -2.19 -2.19 -2.19 1.00
2022-12-31 -2.21 -2.21 -2.21 1.00
2021-12-31 -1.04 -1.04 -1.04 1.00
2020-12-31 -0.81 -0.81 -0.81 1.00
2020-04-08
DB:TG4 Past Financials Data
Date (Data in EUR Millions) EPS *
2019-12-31 -1.35
2019-09-30 -1.42
2019-06-30 -1.49
2019-03-31 -1.25
2018-12-31 -1.01
2018-09-30 -0.21
2018-06-30 0.62
2018-03-31 0.62
2017-12-31 0.63
2017-09-30 -0.52
2017-06-30 -1.67
2017-03-31 -1.67

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Oxurion will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Oxurion's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Oxurion has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Oxurion performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Oxurion's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Oxurion does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare Oxurion's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Oxurion's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Oxurion's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Oxurion Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:TG4 Past Revenue, Cash Flow and Net Income Data
Date (Data in EUR Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 3.95 -51.83 13.28 25.71
2019-09-30 3.66 -54.30 13.58 26.96
2019-06-30 3.38 -56.76 13.89 28.21
2019-03-31 4.35 -47.62 13.23 28.87
2018-12-31 5.32 -38.47 12.57 29.52
2018-09-30 6.07 -7.75 11.61 27.76
2018-06-30 6.82 22.97 10.65 25.99
2018-03-31 6.31 22.88 10.56 24.59
2017-12-31 5.81 22.79 10.47 23.19
2017-09-30 5.84 -18.86 10.49 23.22
2017-06-30 5.87 -60.51 10.50 23.24
2017-03-31 6.49 -60.41 10.68 23.98
2016-12-31 7.10 -60.31 10.85 24.71
2016-09-30 8.15 -47.02 13.81 23.91
2016-06-30 9.20 -33.72 16.78 23.12
2016-03-31 10.20 -35.80 21.19 22.25
2015-12-31 11.20 -37.88 25.59 21.39
2015-09-30 11.90 -42.16 29.97 21.31
2015-06-30 12.61 -46.45 34.35 21.23
2015-03-31 13.19 -48.78 36.87 21.89
2014-12-31 13.78 -51.12 39.39 22.55
2014-09-30 15.49 -51.59 40.29 24.28
2014-06-30 17.21 -52.06 41.19 26.00
2014-03-31 64.99 -12.83 45.20 28.87
2013-12-31 112.78 26.40 49.20 31.73
2013-09-30 107.76 27.63 47.42 27.38
2013-06-30 102.75 28.87 45.63 23.02

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Oxurion has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Oxurion has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Oxurion improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Oxurion's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Oxurion has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Oxurion's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Oxurion's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Oxurion is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Oxurion's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Oxurion's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Oxurion has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Oxurion Company Filings, last reported 3 months ago.

DB:TG4 Past Debt and Equity Data
Date (Data in EUR Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 53.31 0.00 52.94
2019-09-30 53.31 0.00 52.94
2019-06-30 72.28 0.00 67.60
2019-03-31 72.28 0.00 67.60
2018-12-31 105.31 0.00 85.13
2018-09-30 105.31 0.00 85.13
2018-06-30 128.08 0.00 101.43
2018-03-31 128.08 0.00 101.43
2017-12-31 133.36 0.00 105.73
2017-09-30 133.36 0.00 105.73
2017-06-30 94.73 0.00 65.14
2017-03-31 94.73 0.00 65.14
2016-12-31 109.86 0.00 80.07
2016-09-30 109.86 0.00 80.07
2016-06-30 155.05 0.00 91.49
2016-03-31 155.05 0.00 91.49
2015-12-31 170.02 0.00 101.39
2015-09-30 170.02 0.00 101.39
2015-06-30 188.54 0.00 113.29
2015-03-31 188.54 0.00 113.29
2014-12-31 208.01 0.00 127.08
2014-09-30 208.01 0.00 127.08
2014-06-30 234.93 0.00 148.77
2014-03-31 234.93 0.00 148.77
2013-12-31 258.77 0.00 172.36
2013-09-30 258.77 0.00 172.36
2013-06-30 286.69 0.00 193.55
  • Oxurion has no debt.
  • Oxurion has not taken on any debt in the past 5 years.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Oxurion has sufficient cash runway for 1.7 years based on current free cash flow.
  • Oxurion has less than a year of cash runway if free cash flow continues to reduce at historical rates of -9.9% each year.
X
Financial health checks
We assess Oxurion's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Oxurion has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Oxurion's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Oxurion dividends.
If you bought €2,000 of Oxurion shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Oxurion's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Oxurion's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:TG4 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 1.1%
Germany Market Average Dividend Yield Market Cap Weighted Average of 314 Stocks 3.6%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.6%
Germany Top 25% Dividend Yield 75th Percentile 4.6%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:TG4 Future Dividends Estimate Data
Date (Data in €) Dividend per Share (annual) Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2020-04-08

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Oxurion has not reported any payouts.
  • Unable to verify if Oxurion's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Oxurion's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Oxurion has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Oxurion's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Oxurion afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Oxurion has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Oxurion's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Patrik De Haes
COMPENSATION €549,000
TENURE AS CEO 11.6 years
CEO Bio

Dr. Patrik De Haes, ViBio, BVBA, MD, has been the Chief Executive Officer of ThromboGenics NV since September 1, 2008. Dr. De Haes serves as an Executive Director of ThromboGenics NV. Dr. Haes serves as Executive Director, Acting CMO and Chief Executive Officer of Oxurion NV. Dr. De Haes served as the Chief Operating Officer of ThromboGenics NV until September 1, 2008. Previously, he served as Head of the Global Insulin Infusion business at Roche in Switzerland. He served as President and Chief Executive Officer of Disetronic Medical Systems Inc., a leading company in insulin infusion therapy, in Minneapolis, USA. At Sandoz Pharma (Now Novartis) in Switzerland, he led The Global Development and Commercialization of the First Biotech Product for it. He has over 20 years of experience in The Global Health Care Industry, Covering Product Development, Marketing and General Management. Dr. De Haes holds a degree in Medicine from the University of Leuven and a corporate MBA from the University of St. Thomas, Minneapolis, USA. Dr. De Haes holds degree in Marketing Strategy from INSEAD, Fontainebleau, France and MD degree from KULeuven, Belgium.

CEO Compensation
  • Patrik's compensation has been consistent with company performance over the past year, both up more than 20%.
  • Patrik's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure of the Oxurion management team in years:

4.5
Average Tenure
  • The tenure for the Oxurion management team is about average.
Management Team

Patrik De Haes

TITLE
CEO, Acting CMO & Executive Director
COMPENSATION
€549K
TENURE
11.6 yrs

Dominique Vanfleteren

TITLE
Chief Financial Officer
TENURE
5.3 yrs

Jean Feyen

TITLE
Chief Scientific Officer

Wouter Piepers

TITLE
Global Head of Corporate Communications & Investor Relations

Claude Sander

TITLE
Chief Legal Officer

Isabelle Decoster

TITLE
Head of HR

Andy De Deene

TITLE
Global Head of Development

Ove Pedersen

TITLE
Head of Product Supply
AGE
62

Marc Denayer

TITLE
Global Head of Drug Safety & Medical Affairs
TENURE
3.7 yrs

Vinciane Vangeersdaele

TITLE
Chief Commercial Officer
TENURE
2.4 yrs
Board of Directors Tenure

Average tenure and age of the Oxurion board of directors in years:

4.8
Average Tenure
61.5
Average Age
  • The tenure for the Oxurion board of directors is about average.
Board of Directors

Thomas Clay

TITLE
Independent Chairman
COMPENSATION
€46K
AGE
34
TENURE
2.8 yrs

Patrik De Haes

TITLE
CEO, Acting CMO & Executive Director
COMPENSATION
€549K

Emmanuele Attout

TITLE
Non-Executive Independent Director
COMPENSATION
€32K
TENURE
4.9 yrs

David Guyer

TITLE
Non-Executive Director
COMPENSATION
€100K
AGE
59
TENURE
6.3 yrs

Philippe Vlerick

TITLE
Non-Executive Independent Director
COMPENSATION
€21K
AGE
64
TENURE
4.8 yrs

Adrienne Graves

TITLE
Independent Director
COMPENSATION
€7K
AGE
66
TENURE
1.5 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess Oxurion's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Oxurion has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Oxurion NV, an integrated biopharmaceutical company, develops and commercializes medicines that address unmet clinical needs in ophthalmology in Belgium and internationally. The company’s lead product is JETREA used for the treatment of symptomatic vitreomacular adhesion and vitreomacular traction. It also develops THR-317, a placental growth factor (PIGF) neutralizing monoclonal antibody that is in Phase I/II clinical study for the treatment of diabetic macular edema (DME) or diabetic retinopathy (DR); THR-149, a plasma kallikrein inhibitor for treatment of DME; THR-687 a small molecule integrin antagonist to treat patients with DR and/or DME; and TB-403, an anti-PlGF for treatment of medulloblastoma, a pediatric malignant brain tumor. Oxurion NV has collaboration agreements with BioInvent International AB, Bicycle Therapeutics, Outcome Sciences, Inc., Parexel, INC Research, Galapagos, and Beta Therapeutics Pty Ltd. The company was formerly known as ThromboGenics NV and changed its name to Oxurion NV in September 2018. Oxurion NV was founded in 1991 and is headquartered in Leuven, Belgium.

Details
Name: Oxurion NV
TG4
Exchange: DB
Founded: 1991
€98,218,851
38,291,950
Website: http://www.oxurion.com
Address: Oxurion NV
Gaston Geenslaan 1,
Leuven,
Flemish Brabant, 3001,
Belgium
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
ENXTBR OXUR Ordinary Bearer Shares Euronext Brussels BE EUR 07. Jul 2006
OTCPK TBGN.F Ordinary Bearer Shares Pink Sheets LLC US USD 07. Jul 2006
DB TG4 Ordinary Bearer Shares Deutsche Boerse AG DE EUR 07. Jul 2006
LSE 0G99 Ordinary Bearer Shares London Stock Exchange GB EUR 07. Jul 2006
Number of employees
Current staff
Staff numbers
77
Oxurion employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/08 21:39
End of day share price update: 2020/04/08 00:00
Last estimates confirmation: 2020/03/13
Last earnings filing: 2020/04/03
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.